Clinical trial NCT03451006: Effect of Metformin on Frailty in 12 Subjects
Official title: (MATE) Metformin and Aging Trial in the Elderly: A Pilot and Feasibility Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Aging
Inflammation
Frailty
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2018-03-01
Enrollment: 7
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Arms Assigned interventions Placebo Comparator: Metformin Chronic metformin administration through augmentation of cellular regeneration and reduction of senescence will improve frailty and physical functioning as studied by the short physical performance battery (SPPB) test. Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score \<9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months.

Placebo comparator: Placebo Placebo will be compared to chronic metformin administration Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score \<9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months.
Primary purpose: TREATMENT

Brief summary: This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.

Detailed description: Heart disease is the number one cause of death in the United States and disproportionately affects older adults, underscoring the need to examine determinants of survivorship. Recognizing this gap, current guidelines lay emphasis to assess frailty, a key construct prevalent in elderly and known to impact their prognosis.Older persons are commonly frail, manifest hyperglycemia and their health span is truncated by illnesses during which physiological declines together with accumulation of additional deficits results in multimorbidity and functional dependence. High incidence of functional decline and stress hyperglycemia in patients with coronary artery disease (CAD) makes pharmacologic manipulation, an attractive strategy to improve frailty and reduce adverse cardiovascular outcomes. Metformin exerts its effect on health span as a calorie restriction-mimetic through inhibition of mitochondrial complex 1 and activation of activated protein kinase (AMP).This drug is safe and has been shown to prolong life in mammals. Metformin by reducing effects of cellular senescence and improving glycemic control may improve the functioning of older adults.

In CAD, cellular senescence and inflammation affect organ dysfunction through interference with tissue homeostasis and regeneration. The deleterious effect of senescence includes pro-inflammatory senescence-associated secretory phenotype (SASP). Normal biological function through alteration in cellular homeostasis and restoration of glycemic control may be achieved by metformin. The phenotypic manifestations of these changes are incompletely characterized as it is yet unknown whether cell-intrinsic regenerative mechanisms can be translated into clinical improvement in physical performance and whether it's chronic administration is safe in older adults. These major gaps in knowledge hinder utilization of metformin as an agent to promote cellular regeneration and to reduce the impact of cellular senescence.

Targeting frail individuals with high levels of inflammation and SASP factors would necessitate identification of predictors of improvement with metformin in tissue inflammation and function. A clinomics approach implementing simultaneous assessment of clinical impact coupled with serological profiling would provide enhanced understanding of the local and systemic impact mediated by metformin. Through correlation of molecular profiles with phenotypic expression changes, as proposed herein, investigators will enhance understanding of the regenerative impact of metformin and the basis for clinical improvement in the setting of senescence.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 60 years
* Stable CAD
* Prediabetes (one of the following criteria should be met)

  * Fasting plasma glucose: 100-126 mg/dL
  * HbA1C: 5.7-6.4
* Frailty (Short Physical Performance Battery: Score \<9)
* Able to return for follow-up
* Written informed consent

Exclusion criteria:

* Pre-existing or new-onset diabetes
* Any active malignancy, hematological disorder, post organ transplant, immunocompromised
* Cancer requiring treatment in the past 3 years (other than non-melanoma skin cancer)
* Dementia \[mini mental state examination (MMSE \<20)\]
* Disability (need for assistance in \>2 of any six activities on Katz activities of daily living (ADL)46
* Prior stroke with disability
* Acute coronary syndrome \<3months or participating in cardiac rehabilitation
* Severe Parkinson's
* Hepatic insufficiency and/or chronic liver disease (cirrhosis)
* Chronic kidney disease (GFR \< 45 mL/min)
* Taking metformin for any indication
* Acute alcohol intoxication
* Known hypersensitivity to metformin hydrochloride
* Acute/chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma

Primary outcomes:
measure: Change in Frailty
timeFrame: Baseline, 12 months
measure: Change in Balance Score Standing With Feet Close Together
timeFrame: Baseline, 12 months
measure: Change in Balance Score Standing in Semi Tandem Position
timeFrame: Baseline, 12 months
measure: Change in Balance Score Standing in Full Tandem Position
timeFrame: Baseline, 12 months
measure: Change in Gait Speed
timeFrame: Baseline, 12 months
measure: Change in Score, Standing Test From Chair
timeFrame: Baseline,12 months
Secondary outcomes:
measure: Change in Interleukin 6 (pg/ml)
timeFrame: Baseline, 12 months
measure: Change in Matrix Metalloproteinase (ng/ml)
timeFrame: Baseline, 12 months
measure: Change in Plasminogen Activator Inhibitor
timeFrame: Baseline, 12 months
measure: Change in Monocyte Chemotactic Protein-1
timeFrame: Baseline, 12 months
measure: Change in Activin
timeFrame: Baseline, 12 months
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Mandeep Singh
role: PRINCIPAL_INVESTIGATOR
References: